CN109706119B - 扩增造血干细胞的培养体系、方法及其用途 - Google Patents
扩增造血干细胞的培养体系、方法及其用途 Download PDFInfo
- Publication number
- CN109706119B CN109706119B CN201810330298.0A CN201810330298A CN109706119B CN 109706119 B CN109706119 B CN 109706119B CN 201810330298 A CN201810330298 A CN 201810330298A CN 109706119 B CN109706119 B CN 109706119B
- Authority
- CN
- China
- Prior art keywords
- hematopoietic stem
- stem cells
- culture medium
- cell culture
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title claims description 12
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 31
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 23
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 230000003321 amplification Effects 0.000 claims abstract description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 8
- 239000006143 cell culture medium Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 4
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 abstract description 35
- 230000001332 colony forming effect Effects 0.000 abstract description 9
- 230000004069 differentiation Effects 0.000 abstract description 7
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 abstract description 6
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000012136 culture method Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 101710177504 Kit ligand Proteins 0.000 description 10
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 8
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 8
- 102100034195 Thrombopoietin Human genes 0.000 description 8
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000002791 cfu-m Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000004892 erythrocyte colony-forming unit Anatomy 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000055151 human KITLG Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100036462 Delta-like protein 1 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000003611 congenital autoimmune diabetes mellitus Diseases 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 101150013423 dsl-1 gene Proteins 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
Abstract
Description
Claims (6)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810330298.0A CN109706119B (zh) | 2018-04-13 | 2018-04-13 | 扩增造血干细胞的培养体系、方法及其用途 |
PCT/CN2018/083216 WO2019196128A1 (zh) | 2018-04-13 | 2018-04-16 | 扩增造血干细胞的培养体系、方法及其用途 |
PCT/CN2019/081854 WO2019196816A1 (zh) | 2018-04-13 | 2019-04-09 | 丁酸钠的用途及含有丁酸钠的培养体系 |
CN201980001861.2A CN110799641B (zh) | 2018-04-13 | 2019-04-09 | 丁酸钠的用途及含有丁酸钠的培养体系 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810330298.0A CN109706119B (zh) | 2018-04-13 | 2018-04-13 | 扩增造血干细胞的培养体系、方法及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109706119A CN109706119A (zh) | 2019-05-03 |
CN109706119B true CN109706119B (zh) | 2020-11-27 |
Family
ID=66253635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810330298.0A Active CN109706119B (zh) | 2018-04-13 | 2018-04-13 | 扩增造血干细胞的培养体系、方法及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109706119B (zh) |
WO (1) | WO2019196128A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110951686A (zh) * | 2019-11-14 | 2020-04-03 | 武汉济源高科技有限公司 | 一种造血干细胞体外扩增培养体系和方法 |
CN114736862A (zh) * | 2022-05-18 | 2022-07-12 | 诺航生物技术研究院徐州有限公司 | 一种造血干细胞培养基和造血干细胞的体外扩增方法 |
CN115927169B (zh) * | 2022-10-11 | 2023-08-11 | 再造再生医学科技(杭州)有限公司 | 用于扩增cd34+造血干细胞的培养液和体外扩增cd34+造血干细胞的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106455542A (zh) * | 2014-03-26 | 2017-02-22 | 布里格姆及妇女医院股份有限公司 | 用于人造血干/祖细胞的离体扩增的组合物和方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2490702A1 (en) * | 2009-10-19 | 2012-08-29 | Tristem Trading (Cyprus) Limited | Treatment using reprogrammed mature adult cells |
PT3035798T (pt) * | 2013-08-20 | 2018-11-22 | Univ Yeditepe | Meio de criopreservação de células com boro adicionado |
CN104419683A (zh) * | 2013-09-10 | 2015-03-18 | 中国科学院生物物理研究所 | 制备范可尼贫血症患者自体诱导多能干细胞的方法及其应用 |
CN103740757B (zh) * | 2014-01-21 | 2016-04-20 | 中国科学院生物物理研究所 | 一种利用重编程制备猪神经干细胞的方法 |
-
2018
- 2018-04-13 CN CN201810330298.0A patent/CN109706119B/zh active Active
- 2018-04-16 WO PCT/CN2018/083216 patent/WO2019196128A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106455542A (zh) * | 2014-03-26 | 2017-02-22 | 布里格姆及妇女医院股份有限公司 | 用于人造血干/祖细胞的离体扩增的组合物和方法 |
Non-Patent Citations (2)
Title |
---|
"A Novel High-Throughput Screening Platform Reveals an Optimized Cytokine Formulation for Human Hematopoietic Progenitor Cell Expansion";Marina Tarunina 等;《STEM CELLS AND DEVELOPMENT》;20161231;第25卷(第22期);第1709-1720页 * |
"重组人体干细胞因子的表达、复性、纯化及其对脐带血干细胞体外扩增作用研究";范洁 等;《实用临床医学杂志》;10121231;第16卷(第15期);摘要,第21页第1.2.5节 * |
Also Published As
Publication number | Publication date |
---|---|
CN109706119A (zh) | 2019-05-03 |
WO2019196128A1 (zh) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109706119B (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
CN109207427B (zh) | 一种将人造血祖细胞转变为造血干细胞的方法 | |
CN110564686B (zh) | 扩增造血干细胞的组合物、扩增方法、药物组合物和用途 | |
JPH10295369A (ja) | 造血幹細胞の製造方法 | |
Bucar et al. | Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34+-enriched cells | |
CN109207426B (zh) | 一种将人造血祖细胞转变为造血干细胞的方法 | |
CN110669732B (zh) | 组合物在将造血祖细胞重编程为造血干细胞中的用途 | |
CN110799641B (zh) | 丁酸钠的用途及含有丁酸钠的培养体系 | |
JP6348881B2 (ja) | 造血幹細胞及び前駆細胞の製造方法 | |
CN111154721B (zh) | Nk细胞扩增方法 | |
CN110972481B (zh) | 一种组合物及其用途 | |
CN109593716B (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
CN114891744A (zh) | 一种冷冻脐带血nk细胞体外扩增方法 | |
CN109593715B (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
EP4314244A1 (en) | Cell capture and expansion | |
Singh et al. | Evaluation of four methods for processing human cord blood and subsequent study of the expansion of progenitor stem cells isolated using the best method | |
CN114524756B (zh) | 一种羟基蛋氨酸镁及其制备方法 | |
CN109468277A (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
Jones et al. | The monoculture of cord-blood-derived CD34+ cells by an automated, membrane-based dynamic perfusion system with a novel cytokine cocktail | |
CN109593714A (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
CN109609455A (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
JP2006067858A (ja) | 共培養による造血幹細胞の増幅方法 | |
CN116042522A (zh) | 一种基于仿生微载体的规模化扩增人造血干细胞方法 | |
CN109536447A (zh) | 扩增造血干细胞的培养体系、方法及其用途 | |
CN113512529A (zh) | 特异性抗病毒过继免疫细胞ab的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Zhongjie Inventor after: Guo Xiao Inventor after: Chen Ligong Inventor after: Xue Qinglei Inventor after: Wang Xiaofang Inventor before: Guo Xiao Inventor before: Sun Zhongjie Inventor before: Chen Ligong Inventor before: Xue Qinglei Inventor before: Wang Xiaofang |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191114 Address after: 100022 room 1002, block a, Shiyunhaoting, Shuangjing, Chaoyang District, Beijing Applicant after: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. Applicant after: NEWISH TECHNOLOGY (YINCHUAN) Co.,Ltd. Address before: 100176 Beijing Daxing District economic and Technological Development Zone, 18 South West Road, block B, 1 floor, 103 room. Applicant before: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210425 Address after: 100176 room 103, floor 1, block B, No. 18, Xihuan South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee after: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. Patentee after: Baoding Norway Technology Co.,Ltd. Address before: 100022 room 1002, block a, Shiyunhaoting, Shuangjing, Chaoyang District, Beijing Patentee before: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. Patentee before: NEWISH TECHNOLOGY (YINCHUAN) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230714 Address after: Room 103, 1st Floor, Building B, No. 18, West Ring South Road, Daxing District, Beijing 100176 Patentee after: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. Address before: Room 103, floor 1, block B, No. 18, Xihuan South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing 100176 Patentee before: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. Patentee before: Baoding Norway Technology Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Zhongjie Inventor after: Guo Xiao Inventor after: Xue Qinglei Inventor after: Wang Xiaofang Inventor before: Sun Zhongjie Inventor before: Guo Xiao Inventor before: Chen Ligong Inventor before: Xue Qinglei Inventor before: Wang Xiaofang |